News
TOS-358 demonstrates efficacy in wild-type and mutant PI3Kα cancer models. Nov. 14, 2022. Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent ...
TOS-358 demonstrates efficacy in wild-type and mutant PI3Kα cancer models. Nov. 14, 2022. Researchers from Totus Medicines Inc. presented preclinical data for the potent and selective covalent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback